|
WO2021057915A1
|
|
Ep300/cbp inhibitor
|
|
WO2021032161A1
|
|
Halogen-substituted phenylate compound and applications thereof
|
|
WO2020233512A1
|
|
Aromatic amine ar and bet targeting protein degradation chimera compound and use
|
|
CN111825657A
|
|
Dual-function chimeric heterocyclic compound for targeted degradation of androgen receptor and application thereof
|
|
WO2020200209A1
|
|
Aromatic amine compound and use thereof in preparation of ar and brd4 dual inhibitors and regulators
|
|
CN111377871A
|
|
FAK inhibitor and combined medicine thereof
|
|
CN111217802A
|
|
Histone acetylase p300 inhibitor and application thereof
|
|
CN110776508A
|
|
BRD4 inhibitor and preparation method and application thereof
|
|
WO2019242765A1
|
|
Deuterated butyl phthalide compound and use thereof
|
|
WO2019242766A1
|
|
Deuterated mgl-3196 compound and use thereof
|
|
CN110551065A
|
|
Deuterated Lucistanib compound and application thereof
|
|
CN110526916A
|
|
Deuterated Capmatinib compound and application thereof
|
|
AU2019268481A1
|
|
HC-1119 formulation, preparation method and use thereof
|
|
WO2019214587A1
|
|
Deuterated defactinib compound and use thereof
|
|
CN110407833A
|
|
Deuterated Vistusertib compound and purposes
|
|
CN110372598A
|
|
A kind of new method synthesizing deuterated amide and deuterated sulfonamide
|
|
KR20210016515A
|
|
Deuterated imidazolidindione compounds and uses thereof
|
|
WO2019184919A1
|
|
Adamantane-containing compound and use thereof in treating cancer
|
|
CN110305138A
|
|
A kind of compound for the treatment of cancer and application thereof
|
|
WO2019179436A1
|
|
Acid amide compound and use thereof in treatment of cancers
|
